CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); A61P 31/14 (2018.01); C07K 14/18 (2013.01); C07K 14/1825 (2013.01); C12N 7/00 (2013.01); C12N 7/02 (2013.01); C12N 7/06 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55505 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24163 (2013.01); Y02A 50/30 (2018.01)] | 58 Claims |
1. A Zika virus vaccine comprising a Zika virus having an RNA genome corresponding to the DNA sequence provided by SEQ ID NO: 13 or a variant nucleic acid having at least 99% identity to SEQ ID NO: 13, wherein the sequence identity is determined by Needleman-Wunsch homology alignment, wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects,
wherein the neutralizing antibody titer is determined using a microneutralization assay (MN50) following a single administration of the Zika virus vaccine to a subject; and
wherein the Zika virus comprises an E protein having an amino acid sequence provided by SEQ ID NO: 48 and is able to pack a virulent Zika virus.
|